WOODBRIDGE, ON,
Aug. 19, 2014 /PRNewswire/ -
Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal"
or the "Company"), a specialty pharmaceutical company with a focus
on Omega-3 therapies for cardiovascular disease ("CVD") and overall
health, announced today that an article entitled,
"Redox-sensitive induction of Src/PI3-kinase/Akt and MAPKs
pathways activate eNOS in response to EPA:DHA 6:1,"
authored by Faraj Zgheel, Mahmoud Alhosin, Sherzad Rashid, Mélanie Burban, Cyril Auger and Valérie B. Schini-Kerth has been published in the
current issue of the scientific journal PLOS ONE and is
available at
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0105102.
The findings of Zgheel et al. demonstrate that
the sustained endothelial vasodilatory effect of Omega-3
formulations are EPA:DHA ratio and purity dependent and involve
predominantly the endothelial nitric oxide synthase derived nitric
oxide formation.
The Pivotal 6:1 EPA:DHA formulation of
VASCAZEN® was shown to cause the most pronounced
sustained vasodilatory effect when compared to a 1:1 EPA:DHA, pure
EPA or pure DHA. The study published by the researchers of
the University of Strasbourg,
France, is the first to demonstrate that the biological
activity of Omega-3 formulations is not linked to either the ratio
or the purity alone but depends on the interplay of the components
of each respective formulation.
"The significance of these results emphasizes
not only the superior sustained endothelial vasodilatory profile of
Pivotal's VASCAZEN®, but also points to its
beneficial effects in Omega-3 deficient individuals," said Dr.
George Jackowski, Chief Scientific
Officer. "We are very excited that the
VASCAZEN® formulation was superior to the other
existing commercial products in the marketplace in terms of
sustained coronary vasodilation (i.e. increase of blood flow) which
is important for patients with Coronary Heart Disease who have
compromised coronary vessels."
About PLOS ONE
PLOS ONE publishes primary research from
all areas of science and employs a combination of peer review and
post-publication rating and commenting, to maximize the impact of
every report it publishes. We are published by the Public Library
of Science (PLOS), the open-access publisher whose goal is to make
the world's scientific and medical literature a public resource.
All works published in PLOS ONE are Open Access.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded
(OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company
with a focus on cardiovascular disease and overall health. Pivotal
Therapeutics' lead product VASCAZEN® is a
prescription only medical food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease
through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic
acid (DHA) to levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN® is a patented
product available for sale and distribution in Canada.
About VASCAZEN®
VASCAZEN® is currently
available in the U.S. as a prescription only medical food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN®
is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign
patents.
VASCAZEN® has been clinically
shown to correct an Omega-3 deficiency within eight weeks of
treatment with positive concomitant effects on the lipid profiles,
mainly a 48% reduction of triglycerides and an increase of HDL
without negative impact on the LDL-C lipid profile.
VASCAZEN®'s results were achieved with a dose of
3 grams of EPA and DHA per day of a prescription grade, high
purity, uniquely formulated Omega-3.
Disclosure Notice
The information contained in this document is
as of August 19, 2014. This press
release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as
"will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include the following: Pivotal's inability to obtain
additional financing on acceptable terms; growth in costs and
expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments. The CSE has
not reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
SOURCE Pivotal Therapeutics Inc.